.jpg?width=1754&name=SP_Logo_Color_RGB%202020update%20(1).jpg "Orsini Specialty Pharmacy Logo"){kind=logo}
HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
TREATMENT
About the Disease
Homozygous Familial Hypercholesterolemia (HoFH), also known as homozygous FH, is an ultra-rare inherited condition that affects approximately 1,300 patients in the U.S. HoFH occurs when two copies of the familial hypercholesterolemia (FH)-causing genes are inherited, one from each parent, resulting in dangerously high levels (>400 mg/dL) of LDL-C (bad cholesterol). Patients with HoFH are at risk for premature atherosclerotic disease and cardiac events as early as their teenage years.
About our Patient Care
We work with the physician's office and insurance on a patient's behalf so that patients have more time to focus on their treatment and quality of life. We are here to listen, provide counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.
As part of treatment, we provide:
Dedicated Care Team
We provide prescribers and patients with a dedicated care team for each of our disease state programs. This includes a primary pharmacy contact, clinical education, side-effects management, scheduled refill calls, and a direct phone, fax and email address.
Shipping and Coordination of Care
We provide free overnight delivery of medications and necessary medical supplies and manage the coordination of care between prescribers, sites of care, nurses and patients to ensure dispenses and drug delivery align with the date and location of service.
Financial Assistance Coordination
We successfully identify and assist enrolling patients into any and all manufacturer co-pay and foundation support programs in order to minimize a potential financial burden to patients given the high-cost of specialty medications.
24/7 Access to a Pharmacist
We provide prescribers and patients access to a pharmacist 24/7 to ensure patients are always cared for.
Supported Treatments
Click on the specialty drug name below to expand and see more information.
Evkeeza™
Brand Name | Evkeeza™ (evinacumab-dgnb)
Manufacturer | Regeneron Pharmaceuticals, Inc.
Route of Administration | Injection, for Intravenous Use
Approved Indication | Evkeeza is approved by the U.S. Food and Drug Administration (FDA) as an adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies to treat adult and pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH).
Self-Administration | No
Product Website | https://www.evkeeza.com/
Partnering with Prescribers
Licensed prescribers can submit a completed enrollment form directly to our Admission team. We will begin the process and communicate with your office every step of the way.
